-+ 0.00%
-+ 0.00%
-+ 0.00%

Black Diamond Therapeutics hosts investor webcast on Phase 2 silevertinib trial results

PUBT·05/19/2026 12:09:46
Listen to the news
Black Diamond Therapeutics hosts investor webcast on Phase 2 silevertinib trial results
  • Black Diamond Therapeutics will host an investor webcast on May 21, 2026, at 5:30 p.m. ET to present updated results from its Phase 2 trial of silevertinib in frontline EGFR-mutated non-small cell lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.